-transparent.png){kind=logo}
Vindesine is a semisynthetic vinca alkaloïd. The short plasma half-life suggested that continuous infusion can improve the therapeutic results by maintaining a constant plasma level. Twenty one patients (acute lymphoblastic leukemia = 5 cases; blastic crisis of chronic myelocytic leukemia = 6 cases; lymphomas 10 cases) received 5-day Vindesine infusion (0,7 mg/m2/d). All these patients had previously several treatments and were resistant to usual chemotherapies including other vinca alkaloids (76% of cases). Eighteen patients were evaluable for response: 13 (72%) had partial responses or minor regressions. Toxicity was not important. Continuous 5-day infusion of Vindesine might be used widely in patients with blood diseases.
D Maraninchi, and
J A Gastaut, and
N Tubiana, and
Y Carcassonne
January 1974,
Revista brasileira de pesquisas medicas e biologicas,
D Maraninchi, and
J A Gastaut, and
N Tubiana, and
Y Carcassonne
January 1971,
Verhandlungen der Deutschen Gesellschaft fur Pathologie,
D Maraninchi, and
J A Gastaut, and
N Tubiana, and
Y Carcassonne
December 1980,
Medicina clinica,
D Maraninchi, and
J A Gastaut, and
N Tubiana, and
Y Carcassonne
January 1981,
Cancer treatment reports,
D Maraninchi, and
J A Gastaut, and
N Tubiana, and
Y Carcassonne
April 1981,
Zhonghua nei ke za zhi,
D Maraninchi, and
J A Gastaut, and
N Tubiana, and
Y Carcassonne
February 1978,
La Nouvelle presse medicale,
D Maraninchi, and
J A Gastaut, and
N Tubiana, and
Y Carcassonne
January 1973,
Revista brasileira de pesquisas medicas e biologicas,
D Maraninchi, and
J A Gastaut, and
N Tubiana, and
Y Carcassonne
September 1991,
Gan to kagaku ryoho. Cancer & chemotherapy,
D Maraninchi, and
J A Gastaut, and
N Tubiana, and
Y Carcassonne
January 1979,
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
D Maraninchi, and
J A Gastaut, and
N Tubiana, and
Y Carcassonne
June 1978,
MMW, Munchener medizinische Wochenschrift,
